GLP-1 Receptor Agonist

Clinical psychologists warn that the rapid satiety and weight loss brought by GLP-1 drugs may reinforce excessive concern about body shape or become a tool for compensatory behaviors.

Interdisciplinary collaboration—including endocrinology, psychiatry, nutrition, and public health—is key to reducing the risk of eating disorders associated with GLP-1 drugs.

Including eating disorder-related symptoms in the pharmacovigilance scope of GLP-1 drugs means embedding psychological assessment into prescribing, follow-up, and data reporting.

Clinical trials of most GLP-1 drugs did not include eating disorder patients in their primary endpoints, meaning safety data for the drugs in this population are limited.

For eating disorder patients with comorbid obesity, GLP-1 drugs may help control weight-related health risks.

The convenience of obtaining the drugs (such as online prescriptions) lowers the threshold for use and increases the risk of off-label use.

GLP-1 receptor agonists mimic the action of the body's natural glucagon-like peptide-1 (GLP-1), promoting insulin release, inhibiting glucagon secretion, delaying gastric emptying, and acting on the central nervous system to produce a sense of fullness.

Peptide drugs and supplements have been rising in popularity on social media in recent years, especially GLP-1 receptor agonists related to weight loss and BPC-157 used for tissue repair.

Semaglutide is a representative GLP-1 receptor agonist drug, initially used to treat type 2 diabetes and later widely used for weight management due to its weight-loss effects.

In cross-analysis of multiple independent sources, the consensus is that GLP-1 drugs clearly improve metabolic health, and that a correlation exists between metabolic health and aging biomarkers.

At present, GLP-1 drugs slowing biological aging remains a research direction in an early exploratory stage rather than a confirmed clinical conclusion.

Currently the primary endpoints of most large GLP-1 trials (such as SELECT and the STEP series) are cardiovascular events or weight change, not aging indicators.

Prescription use of GLP-1 drugs should strictly follow medical guidelines, and their potential anti-aging benefits should not become a reason for self-medication.

In addition to metabolic regulation, GLP-1 class drugs also exhibit anti-inflammatory and oxidative stress-reducing properties.

GLP-1 (glucagon-like peptide-1) is a hormone secreted by the intestine that stimulates insulin secretion, suppresses appetite, and produces protective signals in multiple organs.

The mechanistic hypothesis for weight-loss drugs slowing aging centers primarily on GLP-1 receptor agonists (such as semaglutide and tirzepatide).

A therapy that ablates the duodenal lining to reset the diseased intestinal lining can reduce HbA1c by more than one percentage point, and there is preliminary evidence suggesting it may prevent weight regain after discontinuation of GLP-1.

Microdose maintenance is an alternative strategy to stopping medication, whereby the dose is reduced to the minimum effective level that can sustain results and maintained long-term.

Clinical nutritionists and sports medicine specialists recommend consuming 1.2–1.6 grams of protein per kilogram of body weight per day and maintaining resistance training while using GLP-1 drugs.

After stopping the medication, the weight that returns is almost entirely fat rather than the muscle that was previously lost.